These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12681201)

  • 1. [Effect of anti-hypertensive therapy with irbesartan on the absolute cardiovascular risk].
    Coca A; Ruilope LM; Calvo C; de la Sierra A; Aranda P; Luque M; Marín-Iranzo R;
    Rev Clin Esp; 2003 Apr; 203(4):183-8. PubMed ID: 12681201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.
    Kintscher U; Bramlage P; Paar WD; Thoenes M; Unger T
    Cardiovasc Diabetol; 2007 Apr; 6():12. PubMed ID: 17407587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fixed-dose combination of zofenopril plus hydrochlorothiazide vs. irbesartan plus hydrochlorothiazide in hypertensive patients with established metabolic syndrome uncontrolled by previous monotherapy. The ZAMES study (Zofenopril in Advanced MEtabolic Syndrome).
    Napoli C; Omboni S; Borghi C;
    J Hypertens; 2016 Nov; 34(11):2287-97. PubMed ID: 27653164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Zofenopril vs. Irbesartan in Combination with a Thiazide Diuretic in Hypertensive Patients with Multiple Risk Factors not Controlled by a Previous Monotherapy: A Review of the Double-Blind, Randomized "Z" Studies.
    Omboni S; Malacco E; Napoli C; Modesti PA; Manolis A; Parati G; Agabiti-Rosei E; Borghi C
    Adv Ther; 2017 Apr; 34(4):784-798. PubMed ID: 28260186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16,600 patients in primary care.
    Bramlage P; Pittrow D; Kirch W
    Curr Med Res Opin; 2004 Oct; 20(10):1625-31. PubMed ID: 15462695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of three months' treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31,793 patients.
    Strutz F; Bramlage P; Paar WD
    Curr Med Res Opin; 2005 Sep; 21(9):1433-40. PubMed ID: 16197662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BP goal achievement in patients with uncontrolled hypertension : results of the treat-to-target post-marketing survey with irbesartan.
    Schrader J; Bramlage P; Lüders S; Thoenes M; Schirmer A; Paar DW
    Clin Drug Investig; 2007; 27(11):783-96. PubMed ID: 17914897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial.
    Lewin AJ; Weir MR
    Clin Ther; 2008 Dec; 30(12):2354-65. PubMed ID: 19167594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the efficacy and safety of irbesartan/hydrochlorothiazide combination therapy with irbesartan monotherapy in the treatment of moderate or severe hypertension in diabetic and obese hypertensive patients: a post-hoc analysis review.
    Neutel JM
    Postgrad Med; 2011 Jul; 123(4):126-34. PubMed ID: 21680997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function.
    Schiffrin EL; Park JB; Pu Q
    J Hypertens; 2002 Jan; 20(1):71-8. PubMed ID: 11791028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of the antihypertensive activity of fosinopril and irbesartan].
    Angulo E; Robles NR; Grois J; Barquero A; Pérez Miranda M
    An Med Interna; 2002 Nov; 19(11):571-5. PubMed ID: 12522893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension.
    Mimran A; Ruilope L; Kerwin L; Nys M; Owens D; Kassler-Taub K; Osbakken M
    J Hum Hypertens; 1998 Mar; 12(3):203-8. PubMed ID: 9579771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
    O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A
    Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The risks and benefits of initial irbesartan/hydrochlorothiazide combination therapy in patients with severe hypertension.
    Lapuerta P; Franklin S
    J Clin Hypertens (Greenwich); 2009 May; 11(5):277-83. PubMed ID: 19534037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden.
    Ekman M; Bienfait-Beuzon C; Jackson J
    J Hum Hypertens; 2008 Dec; 22(12):845-55. PubMed ID: 18633426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting].
    Lehnert H; Bramlage P; Pittrow D; Kirch W
    MMW Fortschr Med; 2003 Oct; 145 Suppl 3():81-7. PubMed ID: 15490772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension.
    Pool JL; Guthrie RM; Littlejohn TW; Raskin P; Shephard AM; Weber MA; Weir MR; Wilson TW; Wright J; Kassler-Taub KB; Reeves RA
    Am J Hypertens; 1998 Apr; 11(4 Pt 1):462-70. PubMed ID: 9607385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical overview of irbesartan: a new angiotensin II receptor antagonist.
    Pouleur HG
    Am J Hypertens; 1997 Dec; 10(12 Pt 2):318S-324S. PubMed ID: 9438776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease.
    von Vigier RO; Zberg PM; Teuffel O; Bianchetti MG
    Eur J Pediatr; 2000 Aug; 159(8):590-3. PubMed ID: 10968237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension.
    Stumpe KO; Haworth D; Hoglund C; Kerwin L; Martin A; Simon T; Masson C; Kassler-Taub K; Osbakken M
    Blood Press; 1998 Jan; 7(1):31-7. PubMed ID: 9551875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.